{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:57:46Z","timestamp":1773309466483,"version":"3.50.1"},"reference-count":6,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/pat.0b013e32834e42df","type":"journal-article","created":{"date-parts":[[2011,12,12]],"date-time":"2011-12-12T20:03:54Z","timestamp":1323720234000},"page":"59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bone marrow with gelatinous transformation associated with residual disease in imatinib mesylate-treated chronic myelogenous leukaemia (CML)"],"prefix":"10.1016","volume":"44","author":[{"given":"Beenu","family":"Thakral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryce","family":"Higa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish","family":"Venkataraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milind M.","family":"Velankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/PAT.0b013e32834e42df_bib0005","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V100.2.435","article-title":"Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months\u2019 experience","volume":"100","author":"Braziel","year":"2002","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e32834e42df_bib0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1309\/A4RGP4LF12GGH8MW","article-title":"Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status","volume":"119","author":"Frater","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1097\/PAT.0b013e32834e42df_bib0015","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1309\/NR81-VCU0-CKW1-4HT9","article-title":"ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response","volume":"117","author":"Hasserjian","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1097\/PAT.0b013e32834e42df_bib0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/00313020903434686","article-title":"Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia","volume":"42","author":"Hong","year":"2010","journal-title":"Pathology"},{"key":"10.1097\/PAT.0b013e32834e42df_bib0025","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000121825","article-title":"Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?","volume":"119","author":"Ram","year":"2008","journal-title":"Acta Haematol"},{"key":"10.1097\/PAT.0b013e32834e42df_bib0030","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ajh.20776","article-title":"Bone marrow aplasia-a rare complication of imatinib therapy in CML patients","volume":"82","author":"Srinivas","year":"2007","journal-title":"Am J Hematol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302516326034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302516326034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:16:24Z","timestamp":1758471384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302516326034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0031302516326034"],"URL":"https:\/\/doi.org\/10.1097\/pat.0b013e32834e42df","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone marrow with gelatinous transformation associated with residual disease in imatinib mesylate-treated chronic myelogenous leukaemia (CML)","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/PAT.0b013e32834e42df","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}